

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International patent classification<sup>6</sup>:</b>  C12N 15/11, A61K 31/70, C07H 21/00, C12Q 1/68	<b>A2</b>	<b>(11) International publication number:</b> WO 99/25819  <b>(43) International publication date:</b>  27 May 1999 (27.05.99)
<b>(21) International application number:</b> PCT/EP98/06868  <b>(22) International filing date:</b> 29 October 1998 (29.10.98)  <b>(30) Data relating to the priority:</b> 197 50 702.6 15 November 1997 (15.11.97) DE  <b>(71) Applicant (for all designated States except US):</b> HOECHST MARION ROUSSEL DEUTSCHLAND GMBH [DE/DE]; Brüningstrasse 50, D-65929 Frankfurt am Main (DE).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (US only):</b> PEYMAN, Anuschirwan [DE/DE]; Zeilsheimer Strasse 46, D-65779 Kelkheim (DE). UHLMANN, Eugen [DE/DE]; Zum Talblick 31, D-61479 Glashütten (DE). WEISER, Caroline [DE/DE]; Karl-Staib- Strasse 37, D-65795 Hattersheim (DE).  <b>(74) Joint Representative:</b> HOECHST MARION ROUSSEL DEUTSCHLAND GMBH; Patent- und Lizenzabteilung, Gebäude K 801, D-65926 Frankfurt am Main (DE).		<b>(81) Designated states:</b> AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HR, HU, ID, IL, IS, JP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ARIPO Patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian Patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European Patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI Patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>Without the International Search Report and to be republished once the report has been received.</i>
<p style="text-align: center;">As printed</p> <b>(54) Title:</b> ANTISENSE OLIGONUCLEOTIDES AGAINST TENASCIN FOR TREATING VITILIGO  <b>(54) Bezeichnung:</b> ANTISENSE OLIGONUKLEOTIDE GEGEN TENASCIN ZUR BEHANDLUNG VON VITILIGO  <b>(57) Abstract</b>  The invention relates to specific, optionally modified oligonucleotides with a length of up to 18 nucleotides. Said oligonucleotides correspond to segments of tenascin-coding sequences or can bind to these sequences. The invention also relates to the production and use of the oligonucleotides, for example for the specific inhibition of the expression of tenascin and for producing medicaments used to treat vitiligo.  <b>(57) Zusammenfassung</b>  Die Erfindung betrifft spezifische, gegebenenfalls modifizierte Oligonukleotide mit einer Länge von bis zu 18 Nukleotiden, die Abschnitten Tenascin-kodierender Sequenzen entsprechen bzw. die an diese Sequenzen binden können, deren Herstellung sowie die Verwendung derselben, beispielsweise zur spezifischen Inhibition der Expression von Tenascin und zur Herstellung von Arzneimitteln, die zur Behandlung von Vitiligo verwendet werden können.		